Skip to main content

Featured

Nine Provinces Just Made It Legal to Order Wine Straight From Other Provinces — Here's What It Means for Your Wallet

  July 24, 2026 If you've ever fallen in love with a bottle of wine on an Okanagan vacation and then discovered you couldn't legally have it shipped home to Ontario, that particular headache just got a lot smaller. On Tuesday, premiers from nine provinces signed a formal agreement to open up direct-to-consumer (DTC) alcohol sales across provincial lines. In plain terms: breweries, wineries, and distilleries in one province will soon be able to sell and ship their products straight to your door in another, without routing everything through a provincial liquor monopoly first. The timing isn't a coincidence. The deal landed roughly 24 hours after U.S. President Donald Trump announced a 50% tariff on Canadian wine, beer, and spirits headed south of the border, set to take effect in August. With one export market getting more expensive, provinces are moving to open up the market next door instead. What it means for you: If you live in Ontario, you'll soon be able to legal...
Post a Comment
Read more

article

Labels

Alzheimer’s Drug Donanemab Receives FDA Advisers’ Endorsement for Slowing Disease Progression

 

A significant milestone has been reached in the fight against Alzheimer’s disease. Eli Lilly’s closely watched Alzheimer’s drug, donanemab, has won the unanimous backing of federal health advisers. The drug is specifically intended for people with mild dementia caused by this brain-robbing disease.

The decision by the Food and Drug Administration (FDA) advisers comes after careful consideration of the drug’s benefits and risks. Donanemab has demonstrated the ability to modestly slow cognitive decline and memory problems associated with Alzheimer’s. Although it’s not a cure, this endorsement represents a promising step forward in managing the disease.

Here are the key points:

  1. Effectiveness: Donanemab has shown effectiveness in slowing cognitive decline. Patients who received monthly intravenous infusions of the drug declined about 35% more slowly than those who received a placebo.
  2. Risk Assessment: The FDA panel weighed the risks, including side effects like brain swelling and bleeding, which will need monitoring. Despite these risks, the panel concluded that the drug’s benefits outweighed them.
  3. Tau Protein Screening: Unlike previous concerns about tau protein screening, most panelists believed there was enough evidence to prescribe the drug broadly without requiring such screening.
  4. FDA Decision: The FDA will make the final decision on approval later this year. If approved, donanemab would become only the second Alzheimer’s drug in the U.S. shown to convincingly slow cognitive decline.

This endorsement brings hope to individuals and families affected by Alzheimer’s, and we eagerly await the FDA’s final decision. Stay tuned for further updates on this groundbreaking development! 

Labels:

Comments

Post a Comment